Analyzing the Outcomes With Different Treatment Techniques in Myeloma
April 17, 2020 01:47am
By Shaji K. Kumar, MD
Nizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.
Nizar Bahlis, MD, University of Calgary, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.
In the trial, close to 50% of patients were over the age of 75 years old, which represents a real practice population of multiple myeloma, says Bahlis. Updated data for progression-free survival (PFS), overall survival, and PFS2 were presented at the 2019 American Society of Hematology Annual Meeting.
PFS in particular showed sustained improvement in favor of daratumumab, lenalidimode, and dexamethasone compared with the doublet alone. The median PFS with this triplet regimen was not reached, and 68% of patients were cancer-free without progression at follow-up. In the control arm, the median PFS was 33 months, and the hazard ratio remains the same at 0.5, according to Bahlis. There was also a 44% reduction in the risk of death in favor of the triplet regimen.